Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Visinin-Like Protein 1 (Vilip-1, VLP-1)

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Neuronal damage
Use
Pharmacodynamic/response
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Recent studies have implicated the neuronal calcium-sensing protein visinin-like 1 protein (Vilip-1) as a peripheral biomarker in Alzheimer disease (AD), but little is known about expression of Vilip-1 in the brains of patients with AD. The goal was to analyze Vilip-1 in patients with early to moderate AD and examine the connection to ERC neuron loss. A meta-analysis of eight eligible studies suggests VLP-1 is significantly higher in AD patients (effect size = 1.355, p < 0.0001). Visinin-like protein 1, also known as VILIP-1, is a calcium-signaling molecule expressed in neurons.

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

University of Pittsburgh Schools of the Health Sciences; Mental Illness Research, Education, and Clinical Center ; Geriatric Research Education and Clinical Center; VA Pittsburgh Healthcare System; Department of Psychiatry, University of Massachusetts School of Medicine; The Litwin-Zucker Research Center for the Study of Alzheimer’s Disease; The Feinstein Institute for Medical Research; The Zucker Hillside Hospital; The North-Shore LIJ Health System; Alzforum meta analysis.

  1. Kirkwood, C. M., MacDonald, M. L., Schempf, T. A., Vatsavayi, A. V., Ikonomovic, M. D., Koppel, J. L., ... & Yates, N. A. (2016). Altered levels of visinin-like protein 1 correspond to regional neuronal loss in Alzheimer disease and frontotemporal lobar degeneration. Journal of Neuropathology & Experimental Neurology, 75(2), 175-182. https://www.ncbi.nlm.nih.gov/pubmed/26769253

  2. “Alzheimer's Disease vs Control: VLP-1 (CSF).” Alzbiomarker. https://www.alzforum.org/alzbiomarker/meta-analysis/alzheimers-disease-vs-control-vlp-1-csf